These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 22641666)

  • 1. ALPK2 is crucial for luminal apoptosis and DNA repair-related gene expression in a three-dimensional colonic-crypt model.
    Yoshida Y; Tsunoda T; Doi K; Fujimoto T; Tanaka Y; Ota T; Ogawa M; Matsuzaki H; Kuroki M; Iwasaki A; Shirasawa S
    Anticancer Res; 2012 Jun; 32(6):2301-8. PubMed ID: 22641666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-dimensionally specific inhibition of DNA repair-related genes by activated KRAS in colon crypt model.
    Tsunoda T; Takashima Y; Fujimoto T; Koyanagi M; Yoshida Y; Doi K; Tanaka Y; Kuroki M; Sasazuki T; Shirasawa S
    Neoplasia; 2010 May; 12(5):397-404. PubMed ID: 20454511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS up-regulates the expression of miR-181a, miR-200c and miR-210 in a three-dimensional-specific manner in DLD-1 colorectal cancer cells.
    Ota T; Doi K; Fujimoto T; Tanaka Y; Ogawa M; Matsuzaki H; Kuroki M; Miyamoto S; Shirasawa S; Tsunoda T
    Anticancer Res; 2012 Jun; 32(6):2271-5. PubMed ID: 22641662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic KRAS regulates miR-200c and miR-221/222 in a 3D-specific manner in colorectal cancer cells.
    Tsunoda T; Takashima Y; Yoshida Y; Doi K; Tanaka Y; Fujimoto T; Machida T; Ota T; Koyanagi M; Kuroki M; Sasazuki T; Shirasawa S
    Anticancer Res; 2011 Jul; 31(7):2453-9. PubMed ID: 21873159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of phosphodiesterase-4 (PDE4) activity triggers luminal apoptosis and AKT dephosphorylation in a 3-D colonic-crypt model.
    Tsunoda T; Ota T; Fujimoto T; Doi K; Tanaka Y; Yoshida Y; Ogawa M; Matsuzaki H; Hamabashiri M; Tyson DR; Kuroki M; Miyamoto S; Shirasawa S
    Mol Cancer; 2012 Jul; 11():46. PubMed ID: 22830422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Alpha-kinase 2 Gene Variant Disrupts Filamentous Actin Localization in the Surface Cells of Colorectal Cancer Spheroids.
    Nishi K; Luo H; Nakabayashi K; Doi K; Ishikura S; Iwaihara Y; Yoshida Y; Tanisawa K; Arai T; Mori S; Sawabe M; Muramatsu M; Tanaka M; Sakata T; Shirasawa S; Tsunoda T
    Anticancer Res; 2017 Jul; 37(7):3855-3862. PubMed ID: 28668886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apremilast Induces Apoptosis of Human Colorectal Cancer Cells with Mutant
    Nishi K; Luo H; Ishikura S; Doi K; Iwaihara Y; Wills L; Baillie GS; Sakata T; Shirasawa S; Tsunoda T
    Anticancer Res; 2017 Jul; 37(7):3833-3839. PubMed ID: 28668883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of a Three-dimensional Floating Cell Culture System for Screening Drugs Targeting KRAS-mediated Signaling Molecules.
    Tsunoda T; Ishikura S; Doi K; Iwaihara Y; Hidesima H; Luo H; Hirose Y; Shirasawa S
    Anticancer Res; 2015 Aug; 35(8):4453-9. PubMed ID: 26168486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occurrence of Aurora A positive multipolar mitoses in distinct molecular classes of colorectal carcinomas and effect of Aurora A inhibition.
    Herz C; Schlürmann F; Batarello D; Fichter CD; Schöpflin A; Münch C; Hauschke D; Werner M; Lassmann S
    Mol Carcinog; 2012 Sep; 51(9):696-710. PubMed ID: 21739483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS-mediated up-regulation of RRM2 expression is essential for the proliferation of colorectal cancer cell lines.
    Yoshida Y; Tsunoda T; Doi K; Tanaka Y; Fujimoto T; Machida T; Ota T; Koyanagi M; Takashima Y; Sasazuki T; Kuroki M; Iwasaki A; Shirasawa S
    Anticancer Res; 2011 Jul; 31(7):2535-9. PubMed ID: 21873171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of the MAP kinase phosphatase DUSP4 is associated with microsatellite instability in colorectal cancer (CRC) and causes increased cell proliferation.
    Gröschl B; Bettstetter M; Giedl C; Woenckhaus M; Edmonston T; Hofstädter F; Dietmaier W
    Int J Cancer; 2013 Apr; 132(7):1537-46. PubMed ID: 22965873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2.
    Mologni L; Dekhil H; Ceccon M; Purgante S; Lan C; Cleris L; Magistroni V; Formelli F; Gambacorti-Passerini CB
    Cancer Res; 2010 Sep; 70(18):7253-63. PubMed ID: 20823162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
    J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations.
    Fischer M; Yen WC; Kapoun AM; Wang M; O'Young G; Lewicki J; Gurney A; Hoey T
    Cancer Res; 2011 Mar; 71(5):1520-5. PubMed ID: 21193546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
    Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
    Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorectal cancer.
    Seiden-Long IM; Brown KR; Shih W; Wigle DA; Radulovich N; Jurisica I; Tsao MS
    Oncogene; 2006 Jan; 25(1):91-102. PubMed ID: 16158056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent inactivation of axon guidance molecule RGMA in human colon cancer through genetic and epigenetic mechanisms.
    Li VS; Yuen ST; Chan TL; Yan HH; Law WL; Yeung BH; Chan AS; Tsui WY; So S; Chen X; Leung SY
    Gastroenterology; 2009 Jul; 137(1):176-87. PubMed ID: 19303019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF.
    Mosakhani N; Lahti L; Borze I; Karjalainen-Lindsberg ML; Sundström J; Ristamäki R; Osterlund P; Knuutila S; Sarhadi VK
    Cancer Genet; 2012 Nov; 205(11):545-51. PubMed ID: 23098991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis.
    Tanaka M; Suzuki HI; Shibahara J; Kunita A; Isagawa T; Yoshimi A; Kurokawa M; Miyazono K; Aburatani H; Ishikawa S; Fukayama M
    Oncogene; 2014 May; 33(19):2454-63. PubMed ID: 23752186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.